Clinical Study on the Treatment of Rhinitis Sicca With Sodium Hyaluronate Adjustable Nasal Irrigator

NCT07308015 | Recruiting Phase 4

• 1 other identifier: 2025052906
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

To observe the therapeutic effect of sodium hyaluronate adjustable nasal irrigator on various types of rhinitis sicca and compare it with the therapeutic effect of the commonly used physiological seawater nasal spray in clinical practice.

Conditions

Rhinitis Sicca

Outcome Measures

Primary Outcomes (1)

• Visual Analogue Scale (VAS)

  Two weeks after the treatment

Secondary Outcomes (1)

• Nasal endoscopy examination score

  Two weeks after the treatment

Study Arms (2)

Control group

ACTIVE COMPARATOR

Physiological seawater adjustable nasal irrigator

Drug: Physiological seawater adjustable nasal irrigator

Experimental group

EXPERIMENTAL

Sodium hyaluronate adjustable nasal irrigator

Drug: Sodium hyaluronate adjustable nasal irrigator

Interventions

Physiological seawater adjustable nasal irrigator DRUG

Nasal spray of Physiological seawater.

Control group

Sodium hyaluronate adjustable nasal irrigator DRUG

Nasal spray of Sodium hyaluronate

Experimental group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Symptoms: Dry nose sensation, little and thick nasal discharge, nosebleeds, itchy nasal cavity, and dryness in the nasopharynx. Physical signs: Nasal endoscopy often reveals dry and congested nasal mucosa, which appears grayish-white or dark red, losing its normal luster. There are often dry, thick secretions, scabs or blood scabs on it. The surface of the nasal mucosa is eroded and ulcers occur. The mucosal lesions are most obvious in the anterior part of the nasal cavity. A diagnosis can be made if one or more of the above symptoms and signs are present.

You may not qualify if:

• Those with dry rhinitis and chronic inflammation of the lower respiratory tract.
• Those confirmed by examination to be caused by certain latent lesions in the mouth, nose, throat, esophagu.s, neck or the whole body
• Those who have used drugs for treating dry rhinitis or other medications within the past 30 days.
• Pregnant or lactating women.
• Those who are allergic to this medicine.
• Those with severe cardiovascular, liver, kidney and hematopoietic system diseases, etc.
• Mentally ill patients.

Sponsors & Collaborators

• China-Japan Union Hospital: lead

Study Sites (1)

China-Japan Union Hospital of Jilin University

Changchun, Jilin, 130000, China

RECRUITING

Central Study Contacts

Cuida Meng, Doctor

CONTACT

86+13596096000; mengcd@jlu.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: China-Japan Union Hospital

Study Record Dates

• First Submitted: December 15, 2025
• First Posted: December 29, 2025
• Study Start: June 16, 2025
• Primary Completion (Estimated): June 12, 2026
• Study Completion (Estimated): June 12, 2026
• Last Updated: December 29, 2025

Record last verified: 2025-12

Locations

CN (1)